Porton Down, UK; 17 November 2011: GW Pharmaceuticals plc (AIM: GWP) today announces that the European Patent Office has granted a patent which protects the composition of the Sativex® formulation. This patent has already been granted in the United States.
The patent, entitled “Cannabinoid Liquid Formulations for Mucosal Administration”, provides an exclusivity period until August 2023.
In addition to this newly granted patent, Sativex®is protected by a number of other patents related to different aspects of the product.
Dr Geoffrey Guy, GW’s Chairman, said, “We are very pleased to have further reinforced the patent estate surrounding Sativex. The grant of this patent is part of a matrix of intellectual property rights which continue to be developed by GW, comprising patents, plant variety rights and proprietary know-how, devised to provide extended protection of Sativex and the cannabinoid pipeline.”
Sativex®is approved in the UK, Spain, Denmark, Czech Republic, Canada and New Zealand as a treatment of Multiple Sclerosis spasticity. The product is also in Phase III clinical development as a treatment for cancer pain.
GW Pharmaceuticals pl:(Today)+ 44 20 7831 3113
Dr Geoffrey Guy, Executive Chairman: (Thereafter) + 44 1980 557000
Justin Gover, Managing Director
Financial Dynamics:+ 44 20 7831 3113
Ben Atwell / John Dineen
GW Nominated Adviser: Peel Hunt LLP:+44 (0)20 7418 8900
James Steel / Vijay Barathan
Notes to Editors
Patent: “Cannabinoid Liquid Formulations for Mucosal Administration”
Patent Number: EP 1542657 / Inventor: Brian Whittle / Patent Abstract: The present invention relates to pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump action spray.
GW was founded in 1998 and listed on the AIM, a market of the London Stock Exchange, in June 2001. Operating under license from the UK Home Office, the company researches and develops cannabinoid pharmaceutical products for patients who suffer from a range of serious ailments, in particular multiple sclerosis and cancer pain. GW has assembled a large in-house scientific team with expertise in cannabinoid science as well as experience in the development of both plant-based prescription pharmaceutical products and medicines containing controlled substances. GW occupies a world leading position in cannabinoids and has developed an extensive international network of the most prominent scientists in the field. For further information, please visitwww.gwpharm.com
This news release may contain forward-looking statements that reflect GWs current expectations regarding future events, including development and regulatory clearance of the GW’s products. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including (inter alia), the success of the GW’s research strategies, the applicability of the discoveries made therein, the successful and timely completion of uncertainties related to the regulatory process, and the acceptance of Sativex®and other products by consumer and medical professionals.